ASTRAZENECA PLC
Insider CIK 901832 · GNMX 10% owner · PHAS 10% owner · ALBO 10% owner · RGLS 10% owner · ETTX 10% owner · VIE 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| VIE Viela Bio, Inc. | U Tender | 2021-03-15 | 2021-03-16 | 14,650,334 | $53.00 | $776.47M | 0 | SEC↗ |
| GNMX Aevi Genomic Medicine, Inc | P Buy | 2019-12-19 | 2020-02-07 | 12,946,900 | — | $0 | 12,946,900 | SEC↗ |
| VIE Viela Bio, Inc. | C Conversion deriv | 2019-10-07 | 2019-10-09 | 14,225,324 | — | $0 | 0 | SEC↗ |
| VIE Viela Bio, Inc. | C Conversion | 2019-10-07 | 2019-10-09 | 14,225,324 | — | $0 | 14,225,334 | SEC↗ |
| VIE Viela Bio, Inc. | P Buy | 2019-10-07 | 2019-10-09 | 425,000 | $19.00 | $8.07M | 14,650,334 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 113,891 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 740,337 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | S Sale deriv | 2018-10-22 | 2018-10-24 | 2,734 | $5.00 | $13.7K | 1,664,217 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 1,664,217 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 113,891 | $0.12 | $13.7K | 1,666,951 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | P Buy | 2018-10-22 | 2018-10-24 | 600,000 | $5.00 | $3.00M | 3,004,554 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion | 2018-10-22 | 2018-10-24 | 2,404,554 | — | $0 | 2,404,554 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion deriv | 2018-09-28 | 2018-10-02 | 33,499,900 | — | $0 | 0 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | P Buy | 2018-09-28 | 2018-10-02 | 246,666 | $15.00 | $3.70M | 2,164,855 | SEC↗ |
| ETTX Entasis Therapeutics Holdi | C Conversion | 2018-09-28 | 2018-10-02 | 1,918,185 | — | $0 | 1,918,189 | SEC↗ |
| ALBO ALBIREO PHARMA, INC. | S Sale | 2017-12-01 | 2017-12-05 | 500,000 | $21.40 | $10.70M | 508,141 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | S Sale | 2014-11-12 | 2014-11-14 | 2,000,000 | $17.00 | $34.00M | 4,250,000 | SEC↗ |